You are here

Threat to Advair from cheap generics greets GSK's new CEO

BT_20170208_SYGSK8WT76_2730536.jpg
GlaxoSmithKline's incoming CEO Emma Walmsley will be taking over the reins at a time when the company's inhaled lung drug Advair faces threat from cheap generics.

London

EMMA Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

Just four days before she moves into the top job on April 1, US

sentifi.com

Market voices on: